54.3 F
San Diego
Thursday, Mar 28, 2024
-Advertisement-
Array

Biocept Inc. Announces CFO Resignation, Names Interim CFO

Biocept Inc., a molecular diagnostics company, announced the resignation and replacement of its Chief Financial Officer Bill Kachioff.

In a statement, the San Diego company said Kachioff – senior vice president and CFO – had voluntarily resigned “to pursue other business opportunities” after four years on the company’s senior management team.

In a prepared statement, Biocept’s chairman David Hale announced the company had already picked an interim successor: Mark Foletta, who has more than 20 years of experience in biotech financial management.

Foletta most recently served as senior vice president and chief financial officer of Amylin Pharmaceuticals from 2000 through its acquisition by Bristol-Myers Squibb in 2012.

At Amylin he was responsible for capital formation, financial management, financial reporting and investor relations and participated in the successful commercial launch of three of the company’s products.

Previously, Foletta held management positions with Intermark Inc. and Triton Group Ltd., and served as an audit manager with Ernst & Young. He serves on the boards of directors of AMN Healthcare Services, Regulus Therapeutics, Dexcom and ViaCyte.

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-